Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
March 29, 2020
RegMed Investors’ (RMi): the coming week ...
March 17, 2020
Regenerative Medicine Earnings Scorecard - Q4/19 - to date
February 29, 2020
An introductory homily followed by a short gospel according to Henry
September 11, 2019
Remember and never forget!
August 5, 2019
Regenerative Medicine Earnings Scorecard - Q2/19 - to date
February 26, 2019
Sage Therapeutics (SAGE) prices 3.33 M share offering at $150.00
January 21, 2019
RegMed Investors’ (RMi): worried about 2019, investors better be!
January 15, 2019
Alnylam Pharmaceuticals (ALNY) priced 5 M share offering at $77.50
November 23, 2018
Regenerative Medicine Earnings Scorecard - Q3/18 - to date
6 hours 16 min ago
RegMed Investors’ (RMi) closing bell: What is not priced in?
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at firstname.lastname@example.org.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors